A Presurgical Study of Oral Silybin-Phosphatidylcholine in Patients with Early Breast Cancer

Lazzeroni, Matteo; Guerrieri-Gonzaga, Aliana; Gandini, Sara; Johansson, Harriet; Serrano, Davide; Cazzaniga, Massimiliano; Aristarco, Valentina; Puccio, Antonella; Mora, Serena; Caldarella, Pietro; Pagani, Gianmatteo; Pruneri, Giancarlo; Riva, Antonella; Petrangolini, Giovanna; Morazzoni, Paolo; DeCensi, Andrea; Bonanni, Bernardo

doi:10.1158/1940-6207.capr-15-0123

Cited by 45 publications

(23 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In both studies, similar to other phenolics, the total concentration of conjugated forms was higher compared with free silybin and EGCG (4-and 2-fold, respectively), suggesting a high rate of phase-II metabolism, although free EGCG was not detected in tumour rather than normal tissues. However, the quantification of conjugates was not performed due to the lack of conjugated standards [65,66]. Similar results (considering the limitations of the conjugated forms quantification) related to the identification of methyl and sulphate of catechins have been observed in two animal studies conducted in mice fed green tea extracts.…”

Section: Bioavailability Of Dietary Phenolics and Their Occurrence Insupporting

confidence: 73%

“…Lazzeroni et al described the disposition of some metabolites in breast tissue. However, they did not observe any effect on NO, IGF-1, and Ki-67 in 12 patients with ER+ breast cancer after consuming 2.8 g/day of a silybin-containing milk thistle extract in combination with phosphatidylcholine for 4 weeks between biopsy diagnosis and resection [65]. The only study dealing with food and BC has been conducted so far by Hardman et al [138].…”

Section: Dietary (Poly)phenols and Clinical Studies In Breast Cancer mentioning

confidence: 95%

“…Other trials with BC patients and phenolics or phenolic-containing products, included the assay of grapeseed [136], milk thistle [65], and red clover [137] extracts, walnuts [138], and also a product containing a mixture of EPA, DHA hydroxytyrosol and curcumin [139]. In one of the pioneer studies dealing with polyphenols and BC, Brooker et al did not find any effect on tissue hardness due to RT in 69 BC patients after consuming a grapeseed proanthocyanidins extract (300 mg/day) for 12 months vs. placebo [136].…”

Section: Dietary (Poly)phenols and Clinical Studies In Breast Cancer mentioning

confidence: 99%

See 2 more Smart Citations

Dietary Phenolics against Breast Cancer. A Critical Evidence-Based Review and Future Perspectives

Ávila‐Gálvez

Giménez‐Bastida

Espı́n

et al. 2020

IJMS

View full text Add to dashboard Cite

Breast cancer (BC) is the most common malignancy and the leading cause of cancer-related death in adult women worldwide. Over 85% of BC cases are non-hereditary, caused by modifiable extrinsic factors related to lifestyle, including dietary habits, which play a crucial role in cancer prevention. Although many epidemiological and observational studies have inversely correlated the fruit and vegetable consumption with the BC incidence, the involvement of their phenolic content in this correlation remains contradictory. During decades, wrong approaches that did not consider the bioavailability, metabolism, and breast tissue distribution of dietary phenolics persist behind the large currently existing gap between preclinical and clinical research. In the present review, we provide comprehensive preclinical and clinical evidence according to physiologically relevant in vitro and in vivo studies. Some dietary phenolics such as resveratrol (RSV), quercetin, isoflavones, epigallocatechin gallate (EGCG), lignans, and curcumin are gaining attention for their chemopreventive properties in preclinical research. However, the clinical evidence of dietary phenolics as BC chemopreventive compounds is still inconclusive. Therefore, the only way to validate promising preclinical results is to conduct clinical trials in BC patients. In this regard, future perspectives on dietary phenolics and BC research are also critically discussed.

show abstract

Section: Bioavailability Of Dietary Phenolics and Their Occurrence Insupporting

confidence: 73%

Section: Dietary (Poly)phenols and Clinical Studies In Breast Cancer mentioning

confidence: 95%

Section: Dietary (Poly)phenols and Clinical Studies In Breast Cancer mentioning

confidence: 99%

See 1 more Smart Citation

Dietary Phenolics against Breast Cancer. A Critical Evidence-Based Review and Future Perspectives

Ávila‐Gálvez

Giménez‐Bastida

Espı́n

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…Conversely to the lack of cancer tissue penetration observed in prostate cancer patients (receiving 13 g per day of silybin-phytosome) [ 180 ], administration of silybin-phosphatidylcholine, 2.8 g daily, 1 month before surgery, to patients with early breast cancer showed a selective accumulation of silybin in breast tumor tissue [ 181 ]. However, clear proof of clinical efficacy as adjuvant in cancer therapy is still lacking.…”

Section: Nrf2-activating Phytochemicals: Senescence Inducers Senomentioning

confidence: 99%

Inducers of Senescence, Toxic Compounds, and Senolytics: The Multiple Faces of Nrf2-Activating Phytochemicals in Cancer Adjuvant Therapy

Malavolta

Bracci

Santarelli

et al. 2018

Mediators of Inflammation

View full text Add to dashboard Cite

The reactivation of senescence in cancer and the subsequent clearance of senescent cells are suggested as therapeutic intervention in the eradication of cancer. Several natural compounds that activate Nrf2 (nuclear factor erythroid-derived 2-related factor 2) pathway, which is involved in complex cytoprotective responses, have been paradoxically shown to induce cell death or senescence in cancer. Promoting the cytoprotective Nrf2 pathway may be desirable for chemoprevention, but it might be detrimental in later stages and advanced cancers. However, senolytic activity shown by some Nrf2-activating compounds could be used to target senescent cancer cells (particularly in aged immune-depressed organisms) that escape immunosurveillance. We herein describe in vitro and in vivo effects of fifteen Nrf2-interacting natural compounds (tocotrienols, curcumin, epigallocatechin gallate, quercetin, genistein, resveratrol, silybin, phenethyl isothiocyanate, sulforaphane, triptolide, allicin, berberine, piperlongumine, fisetin, and phloretin) on cellular senescence and discuss their use in adjuvant cancer therapy. In light of available literature, it can be concluded that the meaning and the potential of adjuvant therapy with natural compounds in humans remain unclear, also taking into account the existence of few clinical trials mostly characterized by uncertain results. Further studies are needed to investigate the therapeutic potential of those compounds that display senolytic activity.

show abstract

“…Silibinin could alleviate mitochondrial dysfunction in mice model of cisplatin-induced acute kidney injury through Sirt3 activation, although in vitro proapoptotic effects through inducing ROS production have been also reported [ 86 , 87 ]. The safe profile with silibinin, evidenced by marketed health food and clinical trials, makes silibinin a very promising candidate for antifungal therapies against Candida infections although there is still a long way to go [ 88 ].…”

Section: Compounds Targeting Mitochondriamentioning

confidence: 99%

Antifungal Compounds againstCandidaInfections from Traditional Chinese Medicine

Liu

Zhang

et al. 2017

BioMed Research International

View full text Add to dashboard Cite

Infections caused by Candida albicans, often refractory and with high morbidity and mortality, cause a heavy burden on the public health while the current antifungal drugs are limited and are associated with toxicity and resistance. Many plant-derived molecules including compounds isolated from traditional Chinese medicine (TCM) are reported to have antifungal activity through different targets such as cell membrane, cell wall, mitochondria, and virulence factors. Here, we review the recent progress in the anti-Candida compounds from TCM, as well as their antifungal mechanisms. Considering the diverse targets and structures, compounds from TCM might be a potential library for antifungal drug development.

show abstract

A Presurgical Study of Oral Silybin-Phosphatidylcholine in Patients with Early Breast Cancer

Abstract: Silybin-phosphatidylcholine is an orally bioavailable complex of silybin, a polyphenolic flavonolignan derived from milk thistle, endowed with potential anticancer activity in preclinical models.

Cited by 45 publications

References 25 publications

Dietary Phenolics against Breast Cancer. A Critical Evidence-Based Review and Future Perspectives

Dietary Phenolics against Breast Cancer. A Critical Evidence-Based Review and Future Perspectives

Inducers of Senescence, Toxic Compounds, and Senolytics: The Multiple Faces of Nrf2-Activating Phytochemicals in Cancer Adjuvant Therapy

Antifungal Compounds againstCandidaInfections from Traditional Chinese Medicine

Contact Info

Product

Resources

About